ポスト

$LXRX With approval and launch, this drug will rapidly gain acceptance as an oral adjunct to insulin therapy in the treatment of T1D, where there are few options. T1D patients are very active in their own care, either to prevent complications or to protect their QOL https://t.co/sRbPAIe0qQ https://t.co/otFakvzWvJ

メニューを開く

キーキーpapa@米国株🍔@papa20366318

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ